[{"id":"7d881018-0265-4ecb-9d18-1c4241cf9170","acronym":"","url":"https://clinicaltrials.gov/study/NCT05199584","created_at":"2022-01-20T14:53:33.589Z","updated_at":"2024-07-02T16:35:26.000Z","phase":"Phase 2","brief_title":"A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations","source_id_and_acronym":"NCT05199584","lead_sponsor":"Endeavor Biomedicines, Inc.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e taladegib (ENV 101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-12-18"},{"id":"fb5922c2-88de-441b-8c08-5a08e614bed9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01919398","created_at":"2021-01-18T08:39:32.118Z","updated_at":"2024-07-02T16:36:55.807Z","phase":"Phase 1","brief_title":"A Study of LY2940680 in Japanese Participants With Advanced Cancers","source_id_and_acronym":"NCT01919398","lead_sponsor":"Eli Lilly and Company","biomarkers":" GLI1","pipe":"","alterations":" ","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e taladegib (ENV 101)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 06/28/2017","study_completion_date":" 06/28/2017","last_update_posted":"2019-09-11"}]